Close Menu

NEW YORK – Kuur Therapeutics reported interim data on Thursday on its autologous GD2-targeting CAR NK-cell therapy, KUR-501, from a Phase I trial involving relapsed or refractory neuroblastoma patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.